Congratulations on receiving one of the United European Gastroenterology (UEG) 2026 Lifetime Achievement Awards. Looking back on your career, what have been the most significant advances in biomedical imaging that you have witnessed, and which developments that you have helped pioneer are you most proud of?
What I have witnessed is an extraordinary evolution of imaging: from relatively basic anatomical images to high-resolution, highly versatile imaging that combines exquisite anatomy with functional and increasingly biological information. MRI is perhaps the best example of that transformation. In cancer imaging, it has been particularly transformative, allowing us to distinguish tumour from normal tissue much more clearly, while also providing information about perfusion, blood vessels, and tumour texture.
What I am most proud of is that we have helped bring imaging to the heart of clinical decision-making, with a direct impact on patients. My pioneering work in rectal cancer MRI is a good example: we have developed MRI from a diagnostic tool into one that can actually guide treatment by identifying risk, helping to plan surgery, assessing response, and selecting patients for organ-preserving strategies. For me, that has always been the real value of innovation in imaging: not simply seeing more of the tumour, but using what we see to make better treatment decisions for individual patients.
Throughout your career, you have held several prominent leadership positions in radiology and medical imaging, including the presidency of the European Society of Radiology (ESR) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR). How important is collaboration between imaging specialists and digestive health professionals, and what role can multidisciplinary societies such as UEG play in strengthening these relationships?
Collaboration is absolutely essential. Imaging only reaches its full potential when it is connected to the clinical need, the clinical question, and the professionals making the treatment decision.
Throughout my leadership roles in Europe, my strategic focus has been on bringing disciplines together and preparing radiology for a future in which imaging and image-guided therapies play an increasingly central role across the patient care pathway.
I actively worked to strengthen collaboration between radiological and other medical societies across Europe, forge strategic alliances with European organisations and EU policymakers, and position radiology as an essential partner in multidisciplinary healthcare.
That is why, for the European Congress of Radiology (ECR) in 2022, I deliberately chose “Building Bridges” as the Congress theme. I made the Congress highly multidisciplinary, inviting professionals from different disciplines, as well as policymakers and organisations, to engage in dialogue with radiologists. For me, it represented more than a congress theme: it marked a new direction for radiology, moving beyond our own professional boundaries, bringing imaging closer to clinical decision-making, and building stronger connections with other medical disciplines.
UEG is a platform for exactly this kind of multidisciplinary collaboration, bringing together gastroenterologists, radiologists, surgeons, oncologists, pathologists, and other professionals. The best innovation happens at the boundaries between disciplines. We need to understand not only what imaging can show, but also what our colleagues need to know to make better decisions for their patients.
I believe this multidisciplinary approach is also an important reason why UEG is recognising my work.
Your work has made a significant contribution to abdominal and oncological radiology, particularly in improving the staging, and treatment of rectal cancer. How has medical imaging transformed the management of rectal cancer, and where do you see the greatest opportunities to improve patient outcomes further?
Imaging has fundamentally changed its position in rectal cancer care. At the beginning of this millennium, MRI provided a much clearer picture of rectal tumours than CT, particularly in the anatomically complex pelvis. This enabled us to identify patients whose tumours extended into surrounding structures and who needed pre-operative radiotherapy rather than proceeding directly to surgery. Imaging therefore moved from simply showing us the disease to helping determine the most appropriate treatment from the outset.
Since then, MRI has evolved further. It can provide information that guides surgical planning and risk assessment, and it has become increasingly important for assessing treatment response and selecting patients for organ-preserving treatment. By repeating MRI after radiotherapy, we can identify patients whose tumours have responded completely and who may no longer need surgery, making follow-up within watch-and-wait strategies possible.
Organ preservation is particularly important to me because it demonstrates how imaging combined with clinical and endoscopic assessment can enable us to move away from a one-size-fits-all approach and avoid unnecessary treatment and toxicity in appropriately selected patients. Our work shows how imaging can become an integral part of personalised treatment rather than simply a diagnostic step.
The next major opportunity is to integrate imaging with information from pathology, laboratory, and molecular biomarkers, as well as clinical information, increasingly supported by AI.
The question will no longer simply be ‘what do we see?’, but increasingly ‘what does all this information mean for this individual patient, and how should it change treatment?’.
You have envisioned a future in which AI transforms the role of the radiologist, potentially shifting the focus from image interpretation towards that of a “medical information specialist.” What might this transformation look like in practice, and what implications could it have for the way radiologists and gastroenterologists collaborate in patient care?
I believe AI will change radiology much more profoundly than simply helping us acquire scans and interpret images faster. We increasingly need to bring together information from imaging, pathology, laboratory, molecular biomarkers, and clinical information. AI gives us the opportunity to integrate these different sources of information and translate them into clinically meaningful insights.
This could fundamentally change how we organise healthcare. Today, different disciplines work within their own departments, each contributing a particular type of medical information. But AI does not restrict itself to departmental boundaries. As it increasingly extracts and integrates information across disciplines, traditional silos may break down, requiring us to understand one another’s expertise and work more closely together. This could shift the radiologist’s role from primarily interpreting images towards becoming more of a medical information specialist, helping to integrate and interpret complex information to support clinical decisions.
Human expertise and oversight will remain essential. The professionals involved may increasingly be defined not only by their traditional specialty, but also by their ability to interpret and share medical information in this more integrated way. Rather than imaging being a report that arrives at the end of a diagnostic process, it can become part of the entire clinical decision-making process, with specialists helping to orchestrate the patient pathway.
I think this will make collaboration between radiologists, gastroenterologists, and other HCPs even more important. But we should never confuse technological performance with clinical value. AI needs to be validated across hospitals and patient groups, work reliably in our own clinical practice and for our own patients, fit into clinical workflows, and demonstrably contribute to better decisions.
The goal is not AI replacing one professional or another; the goal is AI helping us make better decisions together.
Your work spans scientific innovation, clinical practice, and European health policy. How can research and technological innovation help shape European healthcare policy, and what are the main challenges in translating promising advances into safe, effective, and equitable clinical practice across Europe?
I have increasingly realised that scientific innovation and health policy cannot be separated. An innovation has limited value if it works in only one research centre or highly specialised institution. We need to ensure that promising advances can be implemented safely and effectively at scale, so that their benefits reach patients across Europe.
That is why my work has gradually expanded from improving imaging through research and clinical practice towards European innovation and health policy. I have realised that European policy provides an important platform for scaling innovation and accelerating its impact. I served on the European Commission’s Mission Board for Cancer and now coordinate Compass AI, a flagship project under the European Commission’s Apply AI Strategy, aimed at accelerating the safe and effective implementation of AI in healthcare.
For me, policy must start with clinical reality. We have to connect science, technology, HCPs, patients, and policymakers. That is how innovation moves from a promising technology to sustainable improvement in healthcare.
The challenge is not technology alone. A technically excellent algorithm does not automatically translate into good care. We need robust local validation, integration into clinical workflows, clarity about responsibility, and the trust of both HCPs and patients.
I see my role as building bridges between these worlds: medicine, because I am a doctor; science, because I am a researcher; and policy, through my work at the European level.
This year, UEG Week welcomed over 14,000 delegates from diverse countries and disciplines, marking its largest congress to date. What message would you like to share with this year’s attendees, particularly the next generation of clinicians and researchers, about the future of digestive health and the importance of collaboration, innovation, and leadership?
My message to the next generation would be: work across disciplines. The best innovations happen when we work together. Scientific organisations such as UEG can create the environment in which the next generation can build those bridges, challenge existing boundaries, and turn innovation into better care.
A Lifetime Achievement Award may carry one person’s name, but it is never the achievement of one person. My own work has only been possible because of patients who participated in our studies, colleagues across many disciplines who recognised the impact good imaging may have in treatment decision-making, and teams willing to challenge established ways of doing things.




